By Dean Seal
Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus.
The stock was up 5.2% at $15.49 in premarket trading. Shares have risen 50% since the start of the year.
The biotechnology company said Thursday that in its ongoing Phase 1b study, a 150 milligram dose of ABI-4334 showed strong antiviral activity and a mean reduction in plasma hepatitis B virus DNA over 28 days of treatment.
ABI-4334 was well-tolerated, with a favorable safety profile and a half-life that supports once-daily oral dosing, Assembly said.
Enrollment for a final cohort of patients dosed with 400 milligrams of ABI-4334 is expected in the first half of 2025.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 26, 2024 09:00 ET (14:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.